Sort
48,018 grants matching “immunotherapy”
Targeting Tumor Metabolism as a Means of Enhancing Immunotherapy
$367,087Robert David Leone · Johns Hopkins University · R01 · FY2022 · CA
Targeting Tumor Metabolism as a Means of Enhancing Immunotherapy
$367,087Robert David Leone · Johns Hopkins University · R01 · FY2023 · CA
Regulation of antigen presenting cells in the tumor microenvironment by retinoic acid
$367,066Malay Haldar · University Of Pennsylvania · R37 · FY2025 · CA
Inter-metastatic divergency in small cell lung cancer; implications for the design of future immunotherapies
$367,057Jose R Conejo-Garcia · Duke University · R01 · FY2024 · CA
Artif. Antigen Presentation to Sensitize Virus-Spec. TCells for Adoptive Immunoth
$367,027Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2008 · CA
Immunoglobulin GM (γ marker) Allotypes and Immunity to HSV1 in Alzheimerâs Disease
$366,990Janardan P Pandey · Medical University Of South Carolina · R56 · FY2021 · AG
Strategies to enhance immune reconstitution after BMT
$366,957Sloan-Kettering Institute For Cancer Res · R01 · FY2002 · HL
Quantitative Systems Biomedicine and Pharmacology for Multiscale Tissue Damage
$366,936Ashlee Nicole Ford Versypt · Oklahoma State University Stillwater · R35 · FY2019 · GM
PET TRACERS TO MONITOR VACCINE AND IMMUNE THERAPY FOR AD
$366,936University Of Pittsburgh At Pittsburgh · R01 · FY2001 · AG
Structural Studies of a T cell Specific Tyrosine Kinase
$366,926Amy H Andreotti · Iowa State University · R01 · FY2016 · AI
Oncolytic virus bispecific gene delivery for high grade gliomas
$366,900Timothy P Cripe · Research Inst Nationwide Children'S Hosp · U54 · FY2023 · CA
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy
$366,900Timothy P Cripe · Research Inst Nationwide Children'S Hosp · U54 · FY2023 · CA
HSP 110 and its role in cancer therapy
$366,830John R. Subjeck · Roswell Park Cancer Institute Corp · R01 · FY2008 · CA
Project 2: Dual Targeting of B7-H3 in mCRPC
$366,800Kenneth J. Pienta · Johns Hopkins University · P50 · FY2024 · CA
Develop a Therapeutic Nano-vaccine against Head and Neck Cancer
$366,795Yu Leo Lei · University Of Michigan At Ann Arbor · R01 · FY2022 · DE
Role of Neutralizing Antibodies in Transmission of SHIV
$366,758Seattle Biomedical Research Institute · R01 · FY2005 · HD
The Significance of MARCO Expression by Tumor-Pulsed Dendritic Cells
$366,750James J Mule · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2007 · CA
Strategies to enhance immune reconstitution after BMT
$366,750Sloan-Kettering Institute For Cancer Res · R01 · FY2005 · HL
Strategies to enhance immune reconstitution after BMT
$366,750Sloan-Kettering Institute For Cancer Res · R01 · FY2004 · HL
Strategies to enhance immune reconstitution after BMT
$366,750Sloan-Kettering Institute For Cancer Res · R01 · FY2003 · HL
Autoimmune vitiligo and tolerance in the immune response to a melanoma antigen
$366,746Victor H. Engelhard · University Of Virginia · R01 · FY2010 · AI
Targeting eEF2 with the protein translation elongation inhibitor SVC112 in head and neck squamous cancer
$366,727Antonio Jimeno · University Of Colorado Denver · P50 · FY2021 · CA
Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response
$366,683Yi Huang · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
Targeting the liver for immunotherapy in pancreatic cancer
$366,641Gregory L Beatty · University Of Pennsylvania · R01 · FY2024 · CA
Project 5
$366,606Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2007 · CA